FR2700472B1
(en)
|
1993-01-19 |
1995-02-17 |
Rhone Poulenc Rorer Sa |
Synergizing association having an antagonistic effect on the NK1 and NK2 receptors.
|
EP0653208A3
(en)
*
|
1993-11-17 |
1995-10-11 |
Pfizer |
Pharmaceutical agents for treatment or prevention of sunburn.
|
US5610165A
(en)
*
|
1994-02-17 |
1997-03-11 |
Merck & Co., Inc. |
N-acylpiperidine tachykinin antagonists
|
FR2719474B1
(en)
*
|
1994-05-05 |
1996-05-31 |
Oreal |
Use of a substance P antagonist in a cosmetic composition and composition obtained.
|
FR2719476B1
(en)
*
|
1994-05-05 |
1997-05-23 |
Oreal |
Use of a substance P antagonist in a cosmetic composition and composition obtained.
|
US6203803B1
(en)
|
1994-12-14 |
2001-03-20 |
Societe L'oreal S.A. |
Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
|
US5554644A
(en)
*
|
1994-06-08 |
1996-09-10 |
Warner-Lambert Company |
Tachykinin (NK2) antagonists
|
GB9415997D0
(en)
*
|
1994-08-08 |
1994-09-28 |
Merck Sharp & Dohme |
Therapeutic agents
|
FR2728265A1
(en)
*
|
1994-12-19 |
1996-06-21 |
Oreal |
USE OF A SUBSTANCE P ANTAGONIST IN A PHARMACEUTICAL COMPOSITION
|
FR2728165A1
(en)
†
|
1994-12-19 |
1996-06-21 |
Oreal |
USE OF AN ANTAGONIST OF SUBSTANCE P FOR THE TREATMENT OF SKIN REDNESS OF NEUROGENIC ORIGIN
|
EP0737471A3
(en)
*
|
1995-04-10 |
2000-12-06 |
L'oreal |
Use of alkaline earth metal salts as TNF-alpha inhibitor in a topical composition and composition obtained therefrom
|
FR2732598B1
(en)
|
1995-04-10 |
1997-05-09 |
Oreal |
USE OF ALKALINE EARTH METAL SALT FOR THE TREATMENT OF PRURITUS AND EYE OR PALPEBRAL DYSESTHESIA
|
FR2737408B1
(en)
*
|
1995-07-31 |
1997-09-05 |
Oreal |
USE OF A BRADYKININE ANTAGONIST IN A COSMETIC, PHARMACEUTICAL OR DERMATOLOGICAL COMPOSITION AND COMPOSITION OBTAINED
|
FR2738741B1
(en)
*
|
1995-09-19 |
1997-12-05 |
Oreal |
COMPOSITION FOR DYEING KERATINIC FIBERS, CONTAINING AN ANTAGONIST OF SUBSTANCE P
|
TW458774B
(en)
|
1995-10-20 |
2001-10-11 |
Pfizer |
Antiemetic pharmaceutical compositions
|
FR2740341B1
(en)
*
|
1995-10-26 |
1997-12-19 |
Oreal |
USE OF LANTHANIDE SALT, TIN, ZINC, MANGANESE, YTTRIUM, COBALT, BARIUM, STRONTIUM IN A SKIN COMPOSITION
|
FR2740335B1
(en)
*
|
1995-10-26 |
1997-12-19 |
Oreal |
USE OF LANTHANIDE, LITHIUM, TIN, ZINC, MANGANESE OR YTTRIUM SALT AS A SUBSTANCE P ANTAGONIST
|
WO1997045119A1
(en)
*
|
1996-05-24 |
1997-12-04 |
Novartis Ag |
Use of substance p antagonists for treating social phobia
|
CA2273785A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Raymond Baker |
Use of nk-1 receptor antagonists for treating severe anxiety disorders
|
GB9716463D0
(en)
*
|
1997-08-04 |
1997-10-08 |
Merck Sharp & Dohme |
Therapeutic agents
|
JP2000103782A
(en)
*
|
1998-07-31 |
2000-04-11 |
Kyorin Pharmaceut Co Ltd |
Cyclic amine derivative and its production
|
WO2000061558A1
(en)
*
|
1999-04-09 |
2000-10-19 |
Mochida Pharmaceutical Co., Ltd. |
Remedies for neuropathic pain
|
US7163949B1
(en)
|
1999-11-03 |
2007-01-16 |
Amr Technology, Inc. |
4-phenyl substituted tetrahydroisoquinolines and use thereof
|
MXPA02004330A
(en)
|
1999-11-03 |
2004-07-30 |
Albany Molecular Res Inc |
Aryl and heteroaryl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin.
|
NZ523456A
(en)
|
2000-07-11 |
2004-11-26 |
Albany Molecular Res Inc |
Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
|
US7541357B2
(en)
|
2004-07-15 |
2009-06-02 |
Amr Technology, Inc. |
Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
ATE550019T1
(en)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
CIS-4-Ä(4-CHLOROPHENYL)SULFONYLÜ-4-(2,5-DIFLUOROPHENYL)CYCLOHEXANEPROPANE ACID FOR THE TREATMENT OF CANCER
|
GEP20125566B
(en)
|
2005-07-15 |
2012-07-10 |
Amr Technology Inc |
Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
|
AU2006297443B2
(en)
|
2005-09-29 |
2010-08-12 |
Merck Sharp & Dohme Corp. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
CA2664113C
(en)
|
2006-09-22 |
2013-05-28 |
Merck & Co., Inc. |
Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
JP4611444B2
(en)
|
2007-01-10 |
2011-01-12 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
Amide substituted indazoles as poly (ADP-ribose) polymerase (PARP) inhibitors
|
CA2682727C
(en)
|
2007-04-02 |
2016-03-22 |
Banyu Pharmaceutical Co., Ltd. |
Indoledione derivative
|
EP3103791B1
(en)
|
2007-06-27 |
2018-01-31 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
US8598184B2
(en)
|
2008-03-03 |
2013-12-03 |
Tiger Pharmatech |
Protein kinase inhibitors
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
UA105182C2
(en)
|
2008-07-03 |
2014-04-25 |
Ньюрексон, Інк. |
Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
WO2010132487A1
(en)
|
2009-05-12 |
2010-11-18 |
Bristol-Myers Squibb Company |
CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
|
PE20120373A1
(en)
|
2009-05-12 |
2012-05-17 |
Albany Molecular Res Inc |
7 - ([1,2,4] TRIAZOLO [1,5-A] PYRIDIN-6-IL) -4- (3,4-DICHLOROPHENYL) -1,2,3,4-TETRAHYDROISOQUINOLINE
|
CN102458123A
(en)
|
2009-05-12 |
2012-05-16 |
阿尔巴尼分子研究公司 |
Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
|
JP5099731B1
(en)
|
2009-10-14 |
2012-12-19 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Substituted piperidines that increase p53 activity and uses thereof
|
EP2584903B1
(en)
|
2010-06-24 |
2018-10-24 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
US8518907B2
(en)
|
2010-08-02 |
2013-08-27 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
DK2606134T3
(en)
|
2010-08-17 |
2019-07-22 |
Sirna Therapeutics Inc |
RNA Interference-Mediated Inhibition of Hepatitis B Virus (HBV) Gene Expression by Short Interfering Nucleic Acid (siNA)
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
DK2632472T3
(en)
|
2010-10-29 |
2018-03-19 |
Sirna Therapeutics Inc |
RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
US20140045847A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP3358013B1
(en)
|
2012-05-02 |
2020-06-24 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
RU2660429C2
(en)
|
2012-09-28 |
2018-07-06 |
Мерк Шарп И Доум Корп. |
Novel compounds that are erk inhibitors
|
AU2013352568B2
(en)
|
2012-11-28 |
2019-09-19 |
Merck Sharp & Dohme Llc |
Compositions and methods for treating cancer
|
ES2707305T3
(en)
|
2012-12-20 |
2019-04-03 |
Merck Sharp & Dohme |
Imidazopyridines substituted as HDM2 inhibitors
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
EP3706742B1
(en)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
EP3833667B1
(en)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|